{"transactions":[{"id":732103,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36820,"kind":"person","name":"Salva Francisco D.","position":1,"cik":"0001834051","reported_name":"Salva Francisco D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Series A Convertible Non-Redeemable Preferred Stock","published_at":"2026-06-18T20:30:31.000Z","date":"2026-06-16","kind":"exercise","planned":false,"acquired":false,"shares":500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Non-Redeemable Preferred Stock (\"Series A Preferred Stock\") automatically converted into 8,128.1 shares of common stock, for no additional consideration, at 5 p. m. Eastern Time on June 16, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series A Convertible Non-Redeemable Preferred Stock of Azitra, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series A Preferred Stock was sold together with a Series B Common Stock Purchase Warrant to purchase shares of common stock and a Series C Common Stock Purchase Warrant to purchase shares of common stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Non-Redeemable Preferred Stock (\"Series A Preferred Stock\") automatically converted into 8,128.1 shares of common stock, for no additional consideration, at 5 p. m. Eastern Time on June 16, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series A Convertible Non-Redeemable Preferred Stock of Azitra, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series A Preferred Stock was sold together with a Series B Common Stock Purchase Warrant to purchase shares of common stock and a Series C Common Stock Purchase Warrant to purchase shares of common stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Non-Redeemable Preferred Stock (\"Series A Preferred Stock\") automatically converted into 8,128.1 shares of common stock, for no additional consideration, at 5 p. m. Eastern Time on June 16, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series A Convertible Non-Redeemable Preferred Stock of Azitra, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series A Preferred Stock was sold together with a Series B Common Stock Purchase Warrant to purchase shares of common stock and a Series C Common Stock Purchase Warrant to purchase shares of common stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Non-Redeemable Preferred Stock (\"Series A Preferred Stock\") automatically converted into 8,128.1 shares of common stock, for no additional consideration, at 5 p. m. Eastern Time on June 16, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series A Convertible Non-Redeemable Preferred Stock of Azitra, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series A Preferred Stock was sold together with a Series B Common Stock Purchase Warrant to purchase shares of common stock and a Series C Common Stock Purchase Warrant to purchase shares of common stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4064050},"source":{"system":"sec-edgar","filing":"0001493152-26-029345","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315226029345/ownership.xml","form_type":"4"}},{"id":732102,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36820,"kind":"person","name":"Salva Francisco D.","position":1,"cik":"0001834051","reported_name":"Salva Francisco D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-06-18T20:30:31.000Z","date":"2026-06-16","kind":"exercise","planned":false,"acquired":true,"shares":4064050,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Non-Redeemable Preferred Stock (\"Series A Preferred Stock\") automatically converted into 8,128.1 shares of common stock, for no additional consideration, at 5 p. m. Eastern Time on June 16, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series A Convertible Non-Redeemable Preferred Stock of Azitra, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series A Preferred Stock was sold together with a Series B Common Stock Purchase Warrant to purchase shares of common stock and a Series C Common Stock Purchase Warrant to purchase shares of common stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 22,241 Incentive Stock Options held by Mr. Salva and exercisable within 60 days of June 16, 2026."}],"balance_after":4086291,"source":{"system":"sec-edgar","filing":"0001493152-26-029345","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315226029345/ownership.xml","form_type":"4"}},{"id":802839,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":51638,"kind":"person","name":"Staskey Norm","position":1,"cik":"0001971477","reported_name":"Staskey Norm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right To Buy)","published_at":"2026-04-22T21:30:01.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":35524,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the total number of shares of the Company's common stock subject to the option shall vest on the one year anniversary of the date of issuance, the Vesting Commencement Date, and 1/36th of the total number of shares of the Company's common stock subject to the option will vest each calendar month thereafter for the next two years, on the same day of the month as the Vesting Commencement Date"}],"balance_after":35524,"derivative":{"exercise_price":0.2127,"expiration_date":"2036-04-20","underlying":"Common Stock","underlying_shares":35524},"source":{"system":"sec-edgar","filing":"0001493152-26-018597","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315226018597/ownership.xml","form_type":"4"}},{"id":802840,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36820,"kind":"person","name":"Salva Francisco D.","position":1,"cik":"0001834051","reported_name":"Salva Francisco D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (Right To Buy)","published_at":"2026-04-22T21:30:00.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":220879,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the total number of shares of the Company's common stock subject to the option shall vest on the one year anniversary of the date of issuance, the Vesting Commencement Date, and 1/36th of the total number of shares of the Company's common stock subject to the option will vest each calendar month thereafter for the next two years, on the same day of the month as the Vesting Commencement Date."}],"balance_after":220879,"derivative":{"exercise_price":0.2127,"expiration_date":"2036-04-20","underlying":"Common Stock","underlying_shares":220879},"source":{"system":"sec-edgar","filing":"0001493152-26-018596","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315226018596/ownership.xml","form_type":"4"}},{"id":802838,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":51637,"kind":"person","name":"Whitfill Travis","position":1,"cik":"0001830178","reported_name":"Whitfill Travis","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options (Right To Buy)","published_at":"2026-04-22T21:29:59.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":64300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the total number of shares of the Company's common stock subject to the option shall vest on the one year anniversary of the date of issuance, the Vesting Commencement Date, and 1/36th of the total number of shares of the Company's common stock subject to the option will vest each calendar month thereafter for the next two years, on the same day of the month as the Vesting Commencement Date."}],"balance_after":64300,"derivative":{"exercise_price":0.2127,"expiration_date":"2036-04-20","underlying":"Common Stock","underlying_shares":64300},"source":{"system":"sec-edgar","filing":"0001493152-26-018595","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315226018595/ownership.xml","form_type":"4"}},{"id":832334,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36820,"kind":"person","name":"Salva Francisco D.","position":1,"cik":"0001834051","reported_name":"Salva Francisco D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Series C Warrants","published_at":"2026-03-20T20:30:30.000Z","date":"2026-03-18","kind":"purchase","planned":false,"acquired":true,"shares":4064050,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series C Warrants are exercisable upon stockholder approval and will terminate, subject to certain exceptions, upon the 30th calendar day following the date on which Azitra, Inc. publicly announces data from its planned human cosmetic study testing the effect of the filaggrin technology."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series C Warrants are exercisable upon stockholder approval and will terminate, subject to certain exceptions, upon the 30th calendar day following the date on which Azitra, Inc. publicly announces data from its planned human cosmetic study testing the effect of the filaggrin technology."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series C Warrants are exercisable upon stockholder approval and will terminate, subject to certain exceptions, upon the 30th calendar day following the date on which Azitra, Inc. publicly announces data from its planned human cosmetic study testing the effect of the filaggrin technology."}],"balance_after":4064050,"derivative":{"exercise_price":0.123,"underlying":"Common Stock","underlying_shares":4064050},"source":{"system":"sec-edgar","filing":"0001493152-26-011858","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315226011858/ownership.xml","form_type":"4"}},{"id":832333,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36820,"kind":"person","name":"Salva Francisco D.","position":1,"cik":"0001834051","reported_name":"Salva Francisco D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Series B Warrants","published_at":"2026-03-20T20:30:30.000Z","date":"2026-03-18","kind":"purchase","planned":false,"acquired":true,"shares":4064050,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock has stated value of $1,000.00 per share. Each share of Series A Preferred Stock automatically converts into 8,128.1 shares of Common Stock, subject to adjustment from time to time in accordance with its Certificate of Designations, Preferences, as of 5:00 p.m. Eastern time on the 1st business day after the date that the Issuer's stockholders have approved each of (A) an increase in the number of authorized shares of the Issuer's Common Stock to enable the Issuer to issue all of the shares of Common Stock that are issuable upon the conversion of the Series A Preferred Stock and (B) the conversion of the Series A Preferred Stock into Common Stock in accordance with the listing rules of the applicable trading market, and subject to the Issuer filing an amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware evidencing such stockholder approval. The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B Warrants are exercisable upon stockholder approval and will terminate 18 months following the date of stockholder approval."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Warrants are exercisable upon stockholder approval and will terminate 18 months following the date of stockholder approval."}],"balance_after":4064050,"derivative":{"exercise_price":0.123,"underlying":"Common Stock","underlying_shares":4064050},"source":{"system":"sec-edgar","filing":"0001493152-26-011858","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315226011858/ownership.xml","form_type":"4"}},{"id":832332,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36820,"kind":"person","name":"Salva Francisco D.","position":1,"cik":"0001834051","reported_name":"Salva Francisco D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Series A Convertible Non-Redeemable Preferred Stock","published_at":"2026-03-20T20:30:30.000Z","date":"2026-03-18","kind":"purchase","planned":false,"acquired":true,"shares":500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock has stated value of $1,000.00 per share. Each share of Series A Preferred Stock automatically converts into 8,128.1 shares of Common Stock, subject to adjustment from time to time in accordance with its Certificate of Designations, Preferences, as of 5:00 p.m. Eastern time on the 1st business day after the date that the Issuer's stockholders have approved each of (A) an increase in the number of authorized shares of the Issuer's Common Stock to enable the Issuer to issue all of the shares of Common Stock that are issuable upon the conversion of the Series A Preferred Stock and (B) the conversion of the Series A Preferred Stock into Common Stock in accordance with the listing rules of the applicable trading market, and subject to the Issuer filing an amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware evidencing such stockholder approval. The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock has stated value of $1,000.00 per share. Each share of Series A Preferred Stock automatically converts into 8,128.1 shares of Common Stock, subject to adjustment from time to time in accordance with its Certificate of Designations, Preferences, as of 5:00 p.m. Eastern time on the 1st business day after the date that the Issuer's stockholders have approved each of (A) an increase in the number of authorized shares of the Issuer's Common Stock to enable the Issuer to issue all of the shares of Common Stock that are issuable upon the conversion of the Series A Preferred Stock and (B) the conversion of the Series A Preferred Stock into Common Stock in accordance with the listing rules of the applicable trading market, and subject to the Issuer filing an amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware evidencing such stockholder approval. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock has stated value of $1,000.00 per share. Each share of Series A Preferred Stock automatically converts into 8,128.1 shares of Common Stock, subject to adjustment from time to time in accordance with its Certificate of Designations, Preferences, as of 5:00 p.m. Eastern time on the 1st business day after the date that the Issuer's stockholders have approved each of (A) an increase in the number of authorized shares of the Issuer's Common Stock to enable the Issuer to issue all of the shares of Common Stock that are issuable upon the conversion of the Series A Preferred Stock and (B) the conversion of the Series A Preferred Stock into Common Stock in accordance with the listing rules of the applicable trading market, and subject to the Issuer filing an amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware evidencing such stockholder approval. The Series A Preferred Stock has no expiration date."}],"balance_after":500,"derivative":{"exercise_price":0.123,"underlying":"Common Stock","underlying_shares":4064050},"source":{"system":"sec-edgar","filing":"0001493152-26-011858","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315226011858/ownership.xml","form_type":"4"}},{"id":961000,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":51637,"kind":"person","name":"Whitfill Travis","position":1,"cik":"0001830178","reported_name":"Whitfill Travis","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options (Right To Buy)","published_at":"2025-12-22T22:28:27.000Z","date":"2025-12-19","kind":"grant","planned":false,"acquired":true,"shares":23724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares of the Company's Common Stock subject to the Option shall vest on the date of issuance, the Vesting Commencement Date, and the remaining balance shall vest in equal monthly installments over the next 36 months of continuous service thereafter."}],"balance_after":23724,"derivative":{"exercise_price":0.2968,"expiration_date":"2035-12-19","underlying":"Common Stock","underlying_shares":23724},"source":{"system":"sec-edgar","filing":"0001493152-25-028849","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315225028849/ownership.xml","form_type":"4"}},{"id":960999,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36820,"kind":"person","name":"Salva Francisco D.","position":1,"cik":"0001834051","reported_name":"Salva Francisco D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (Right To Buy)","published_at":"2025-12-22T22:28:26.000Z","date":"2025-12-19","kind":"grant","planned":false,"acquired":true,"shares":59309,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares of the Company's Common Stock subject to the Option shall vest on the date of issuance, the Vesting Commencement Date, and the remaining balance shall vest in equal monthly installments over the next 36 months of continuous service thereafter."}],"balance_after":59309,"derivative":{"exercise_price":0.2968,"expiration_date":"2035-12-19","underlying":"Common Stock","underlying_shares":59309},"source":{"system":"sec-edgar","filing":"0001493152-25-028846","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315225028846/ownership.xml","form_type":"4"}},{"id":960998,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":57,"kind":"person","name":"Ryan Barbara","position":1,"cik":"0001827169","reported_name":"Ryan Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right To Buy)","published_at":"2025-12-22T22:28:24.000Z","date":"2025-12-19","kind":"grant","planned":false,"acquired":true,"shares":3003,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares of the Company's Common Stock subject to the Option shall vest on the date of issuance, the Vesting Commencement Date, and the remaining balance shall vest in equal monthly installments over the next 36 months of continuous service thereafter."}],"balance_after":3003,"derivative":{"exercise_price":0.2968,"expiration_date":"2035-12-19","underlying":"Common Stock","underlying_shares":3003},"source":{"system":"sec-edgar","filing":"0001493152-25-028845","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315225028845/ownership.xml","form_type":"4"}},{"id":960997,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":51638,"kind":"person","name":"Staskey Norm","position":1,"cik":"0001971477","reported_name":"Staskey Norm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right To Buy)","published_at":"2025-12-22T22:28:23.000Z","date":"2025-12-19","kind":"grant","planned":false,"acquired":true,"shares":15015,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares of the Company's Common Stock subject to the Option shall vest on the date of issuance, the Vesting Commencement Date, and the remaining balance shall vest in equal monthly installments over the next 36 months of continuous service thereafter."}],"balance_after":15015,"derivative":{"exercise_price":0.2968,"expiration_date":"2035-12-19","underlying":"Common Stock","underlying_shares":15015},"source":{"system":"sec-edgar","filing":"0001493152-25-028848","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315225028848/ownership.xml","form_type":"4"}},{"id":960996,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":26270,"kind":"person","name":"Schroer John R.","position":1,"cik":"0001744578","reported_name":"Schroer John R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right To Buy)","published_at":"2025-12-22T22:28:21.000Z","date":"2025-12-19","kind":"grant","planned":false,"acquired":true,"shares":3003,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares of the Company's Common Stock subject to the Option shall vest on the date of issuance, the Vesting Commencement Date, and the remaining balance shall vest in equal monthly installments over the next 36 months of continuous service thereafter."}],"balance_after":3003,"derivative":{"exercise_price":0.2968,"expiration_date":"2035-12-19","underlying":"Common Stock","underlying_shares":3003},"source":{"system":"sec-edgar","filing":"0001493152-25-028847","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315225028847/ownership.xml","form_type":"4"}},{"id":1556384,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":51638,"kind":"person","name":"Staskey Norm","position":1,"cik":"0001971477","reported_name":"Staskey Norm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-04-02T01:51:59.000Z","date":"2024-03-29","kind":"purchase","planned":false,"acquired":true,"shares":47600,"price":0.2108,"value":10034.08,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported shares were purchased in the open market in multiple transactions at prices ranging from $0.20 to $0.2168 . The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Azitra, Inc., any stockholder of Azitra, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1)."}],"balance_after":51100,"source":{"system":"sec-edgar","filing":"0001493152-24-012606","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315224012606/ownership.xml","form_type":"4"}},{"id":1640997,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":51637,"kind":"person","name":"Whitfill Travis","position":1,"cik":"0001830178","reported_name":"Whitfill Travis","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-02-16T01:42:23.000Z","date":"2024-02-13","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":0.3,"value":4500.0,"ownership":{"direct":true},"balance_after":334500,"source":{"system":"sec-edgar","filing":"0001493152-24-006916","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315224006916/ownership.xml","form_type":"4"}},{"id":1640996,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":51638,"kind":"person","name":"Staskey Norm","position":1,"cik":"0001971477","reported_name":"Staskey Norm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-16T01:39:44.000Z","date":"2024-02-13","kind":"purchase","planned":false,"acquired":true,"shares":3300,"price":0.3,"value":990.0,"ownership":{"direct":true},"balance_after":3500,"source":{"system":"sec-edgar","filing":"0001493152-24-006914","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315224006914/ownership.xml","form_type":"4"}},{"id":1640995,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36820,"kind":"person","name":"Salva Francisco D.","position":1,"cik":"0001834051","reported_name":"Salva Francisco D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-02-16T01:38:23.000Z","date":"2024-02-13","kind":"purchase","planned":false,"acquired":true,"shares":333300,"price":0.3,"value":99990.0,"ownership":{"direct":true},"balance_after":338300,"source":{"system":"sec-edgar","filing":"0001493152-24-006912","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315224006912/ownership.xml","form_type":"4"}},{"id":1767580,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":51638,"kind":"person","name":"Staskey Norm","position":1,"cik":"0001971477","reported_name":"Staskey Norm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right To Buy)","published_at":"2023-10-03T20:05:31.000Z","date":"2023-09-08","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares of the Company's Common Stock subject to the Option shall vest after 12 months of continuous service measured from 09/08/2023, the Vesting Commencement Date, and the remaining balance shall vest in equal monthly installments over the next 36 months of continuous service thereafter."}],"balance_after":10000,"derivative":{"exercise_price":2.07,"expiration_date":"2033-09-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001493152-23-035230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315223035230/ownership.xml","form_type":"4"}},{"id":1767579,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":51637,"kind":"person","name":"Whitfill Travis","position":1,"cik":"0001830178","reported_name":"Whitfill Travis","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options (Right To Buy)","published_at":"2023-10-03T20:05:28.000Z","date":"2023-09-08","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares of the Company's Common Stock subject to the Option shall vest after 12 months of continuous service measured from 09/08/2023, the Vesting Commencement Date, and the remaining balance shall vest in equal monthly installments over the next 36 months of continuous service thereafter."}],"balance_after":103152,"derivative":{"exercise_price":2.07,"expiration_date":"2033-09-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001493152-23-035231","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315223035231/ownership.xml","form_type":"4"}},{"id":1767578,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":26270,"kind":"person","name":"Schroer John R.","position":1,"cik":"0001744578","reported_name":"Schroer John R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right To Buy)","published_at":"2023-10-03T20:05:25.000Z","date":"2023-09-08","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares of the Company's Common Stock subject to the Option shall vest after 12 months of continuous service measured from 06/21/2023, the Vesting Commencement Date, and the remaining balance shall vest in equal monthly installments over the next 36 months of continuous service thereafter."}],"balance_after":10000,"derivative":{"exercise_price":2.07,"expiration_date":"2033-09-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001493152-23-035229","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315223035229/ownership.xml","form_type":"4"}},{"id":1767577,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":57,"kind":"person","name":"Ryan Barbara","position":1,"cik":"0001827169","reported_name":"Ryan Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right To Buy)","published_at":"2023-10-03T20:05:21.000Z","date":"2023-09-08","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares of the Company's Common Stock subject to the Option shall vest after 12 months of continuous service measured from 06/21/2023, the Vesting Commencement Date, and the remaining balance shall vest in equal monthly installments over the next 36 months of continuous service thereafter."}],"balance_after":10000,"derivative":{"exercise_price":2.07,"expiration_date":"2033-09-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001493152-23-035228","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315223035228/ownership.xml","form_type":"4"}},{"id":1824314,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2023-07-24T17:51:04.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":1307401,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1307401},"source":{"system":"sec-edgar","filing":"0001578563-23-000065","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856323000065/primary_doc.xml","form_type":"4"}},{"id":1824313,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-24T17:51:04.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":1307401,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":1307401,"source":{"system":"sec-edgar","filing":"0001578563-23-000065","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856323000065/primary_doc.xml","form_type":"4"}},{"id":1842035,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":111788,"kind":"person","name":"McClary Andrew","position":1,"cik":"0001972173","reported_name":"McClary Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Unsecured convertible promissory note","published_at":"2023-06-29T20:56:46.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"price":0,"reported_value":106093,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The unsecured convertible note, including principal and accrued interest in the amount of $106,093.15, automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The unsecured convertible note, including principal and accrued interest in the amount of $106,093.15, automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by KdT Ventures Fund I, LP, of which Mr. McClary is the managing partner."}],"balance_after":0,"derivative":{"exercise_price":2.5,"underlying":"Common Stock","underlying_shares":42437},"source":{"system":"sec-edgar","filing":"0001493152-23-022948","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315223022948/ownership.xml","form_type":"4/A","original_submission_date":"2023-06-26"}},{"id":1842034,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":111788,"kind":"person","name":"McClary Andrew","position":1,"cik":"0001972173","reported_name":"McClary Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Convertible Preferred Stock, par value $0.0001","published_at":"2023-06-29T20:56:46.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":32030,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A preferred stock automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $4.8146 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A preferred stock automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $4.8146 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by KdT Ventures Fund I, LP, of which Mr. McClary is the managing partner."}],"balance_after":0,"derivative":{"exercise_price":4.8146,"underlying":"Common stock","underlying_shares":249474},"source":{"system":"sec-edgar","filing":"0001493152-23-022948","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315223022948/ownership.xml","form_type":"4/A","original_submission_date":"2023-06-26"}},{"id":1842033,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":111788,"kind":"person","name":"McClary Andrew","position":1,"cik":"0001972173","reported_name":"McClary Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock, $0.0001 par value","published_at":"2023-06-29T20:56:46.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":42437,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The unsecured convertible note, including principal and accrued interest in the amount of $106,093.15, automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by KdT Ventures Fund I, LP, of which Mr. McClary is the managing partner."}],"balance_after":291911,"source":{"system":"sec-edgar","filing":"0001493152-23-022948","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315223022948/ownership.xml","form_type":"4/A","original_submission_date":"2023-06-26"}},{"id":1842032,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":111788,"kind":"person","name":"McClary Andrew","position":1,"cik":"0001972173","reported_name":"McClary Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock, $0.0001 par value","published_at":"2023-06-29T20:56:46.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":249474,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A preferred stock automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $4.8146 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by KdT Ventures Fund I, LP, of which Mr. McClary is the managing partner."}],"balance_after":249474,"source":{"system":"sec-edgar","filing":"0001493152-23-022948","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315223022948/ownership.xml","form_type":"4/A","original_submission_date":"2023-06-26"}},{"id":1844242,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":111788,"kind":"person","name":"McClary Andrew","position":1,"cik":"0001972173","reported_name":"McClary Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Unsecured convertible note","published_at":"2023-06-26T10:15:25.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"price":2.5,"reported_value":42437,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The unsecured convertible note, including principal and accrued interest in the amount of $105,867.50, automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The unsecured convertible note, including principal and accrued interest in the amount of $105,867.50, automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The unsecured convertible note, including principal and accrued interest in the amount of $105,867.50, automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are held by KdT Ventures Fund I, LP, of which Mr. McClary is the managing partner."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":16975},"source":{"system":"sec-edgar","filing":"0001493152-23-022334","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315223022334/ownership.xml","form_type":"4"}},{"id":1844241,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":111788,"kind":"person","name":"McClary Andrew","position":1,"cik":"0001972173","reported_name":"McClary Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Convertible Preferred Stock, par value $0.0001","published_at":"2023-06-26T10:15:25.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":249474,"price":2.5,"value":623685.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A preferred stock automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A preferred stock automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The shares of Series A preferred stock automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by KdT Ventures Fund I, LP, of which Mr. McClary is the managing partner."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":42347},"source":{"system":"sec-edgar","filing":"0001493152-23-022334","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315223022334/ownership.xml","form_type":"4"}},{"id":1844240,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":111788,"kind":"person","name":"McClary Andrew","position":1,"cik":"0001972173","reported_name":"McClary Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock, $0.0001 par value","published_at":"2023-06-26T10:15:25.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":16975,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The unsecured convertible note, including principal and accrued interest in the amount of $105,867.50, automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by KdT Ventures Fund I, LP, of which Mr. McClary is the managing partner."}],"balance_after":16975,"source":{"system":"sec-edgar","filing":"0001493152-23-022334","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315223022334/ownership.xml","form_type":"4"}},{"id":1844239,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":111788,"kind":"person","name":"McClary Andrew","position":1,"cik":"0001972173","reported_name":"McClary Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock, $0.0001 par value","published_at":"2023-06-26T10:15:25.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":42347,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A preferred stock automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by KdT Ventures Fund I, LP, of which Mr. McClary is the managing partner."}],"balance_after":42347,"source":{"system":"sec-edgar","filing":"0001493152-23-022334","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315223022334/ownership.xml","form_type":"4"}},{"id":1845247,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36820,"kind":"person","name":"Salva Francisco D.","position":1,"cik":"0001834051","reported_name":"Salva Francisco D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-06-24T00:39:16.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":5,"value":25000.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001493152-23-022316","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315223022316/ownership.xml","form_type":"4"}},{"id":1845345,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":397600,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Azitra Co-Invest I, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments.  The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments.  The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments.  The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":397600},"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":34,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845344,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":22798,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":22798},"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":33,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845343,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":101842,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments.  The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments.  The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments.  The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":101842},"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":32,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845342,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":170272,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":170272},"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845341,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":412389,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments.  The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments.  The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments.  The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":412389},"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845340,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":52078,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":52078},"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845339,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":232908,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments.  The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments.  The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments.  The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":232908},"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845338,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":799467,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund I, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO.  The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO.  The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO.  The Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":799467},"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845337,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":467613,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund I QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO.  The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO.  The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO.  The Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":467613},"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845336,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":130498,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":130498},"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845335,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":808058,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":808058},"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845334,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":123718,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":123718},"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845333,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":436173,"ownership":{"direct":false,"nature":"Directly held by Bios Azitra Co-Invest I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments.  The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":436173,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845332,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":25280,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":137000,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845331,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":111720,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments.  The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":111720,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845330,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":188810,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":1023442,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845329,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":834632,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments.  The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":834632,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845328,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":57747,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":313250,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845327,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":255503,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments.  The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":255503,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845326,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":799467,"ownership":{"direct":false,"nature":"Directly held by Bios Fund I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO.  The Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":799467,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845325,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":467613,"ownership":{"direct":false,"nature":"Directly held by Bios Fund I QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO.  The Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":467613,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845324,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":144705,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":426944,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845323,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"purchase","planned":false,"acquired":true,"shares":73708,"price":5,"value":368540.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":282239,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845322,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"purchase","planned":false,"acquired":true,"shares":208531,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to $2.50 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":208531,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845321,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Notes","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"sale","planned":false,"acquired":false,"shares":82223,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to $2.50 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845320,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":896035,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":2643705,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845319,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"purchase","planned":false,"acquired":true,"shares":456412,"price":5,"value":2282060.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":1747670,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845318,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"purchase","planned":false,"acquired":true,"shares":1291258,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to $2.50 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":1291258,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845317,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Notes","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"sale","planned":false,"acquired":false,"shares":509141,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to $2.50 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845316,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":137186,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments.  The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":404767,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845315,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"purchase","planned":false,"acquired":true,"shares":69880,"price":5,"value":349400.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":267581,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845314,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"purchase","planned":false,"acquired":true,"shares":197701,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to $2.50 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":197701,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845313,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":2,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":3,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":4,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":5,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":6,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":7,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":8,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":9,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":10,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Notes","published_at":"2023-06-23T21:38:21.000Z","date":"2023-06-21","kind":"sale","planned":false,"acquired":false,"shares":77953,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to $2.50 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-074425","document":"tm2319609-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465923074425/tm2319609-2_4seq1.xml","form_type":"4"}},{"id":1845912,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":397600,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Azitra Co-Invest I, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":397600},"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":36,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845911,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":22798,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":22798},"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":35,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845910,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":101842,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":101842},"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":34,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845909,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":170272,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":170272},"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":33,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845908,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":412389,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":412389},"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":32,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845907,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":52078,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":52078},"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845906,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":232908,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":232908},"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845905,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":799467,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund I, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":799467},"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845904,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":467613,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund I QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":467613},"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845903,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":130498,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":130498},"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845902,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":808058,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":808058},"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845901,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":123718,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":123718},"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845900,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":436173,"ownership":{"direct":false,"nature":"Directly held by Bios Azitra Co-Invest I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":436173,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845899,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":25280,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":137000,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845898,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":111720,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":111720,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845897,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":188810,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":1023442,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845896,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":834632,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":834632,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845895,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":57747,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":313250,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845894,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":255503,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":255503,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845893,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":799467,"ownership":{"direct":false,"nature":"Directly held by Bios Fund I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":799467,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845892,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":467613,"ownership":{"direct":false,"nature":"Directly held by Bios Fund I QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":467613,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845891,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":144705,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":426944,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845890,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"purchase","planned":false,"acquired":true,"shares":73708,"price":5,"value":368540.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":282239,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845889,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"purchase","planned":false,"acquired":true,"shares":208531,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to $2.50 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":208531,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845888,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Notes","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"sale","planned":false,"acquired":false,"shares":82223,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to $2.50 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845887,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":896035,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":2643705,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845886,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"purchase","planned":false,"acquired":true,"shares":456412,"price":5,"value":2282060.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":1747670,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845885,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"purchase","planned":false,"acquired":true,"shares":1291258,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to $2.50 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":1291258,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845884,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Notes","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"sale","planned":false,"acquired":false,"shares":509141,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to $2.50 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845883,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":137186,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":404767,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845882,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"purchase","planned":false,"acquired":true,"shares":69880,"price":5,"value":349400.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":267581,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845881,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"purchase","planned":false,"acquired":true,"shares":197701,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to $2.50 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":197701,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845880,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":7,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112003,"kind":"organization","name":"BIOS Azitra Co-Invest I, LP","position":8,"cik":"0001769262","reported_name":"BIOS Azitra Co-Invest I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Notes","published_at":"2023-06-23T21:37:38.000Z","date":"2023-06-21","kind":"sale","planned":false,"acquired":false,"shares":77953,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to $2.50 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\") and Bios Fund I QP, LP (\"Bios Fund I QP\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Azitra Co-invest I, LP (\"Bios Azitra Co-invest\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\") and Bios Fund III NT, LP (\"Bios Fund III NT\"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-074424","document":"tm2319609-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465923074424/tm2319609-1_4seq1.xml","form_type":"4"}},{"id":1845248,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":51637,"kind":"person","name":"Whitfill Travis","position":1,"cik":"0001830178","reported_name":"Whitfill Travis","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-06-23T21:28:14.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":250,"price":5,"value":1250.0,"ownership":{"direct":true},"balance_after":250,"source":{"system":"sec-edgar","filing":"0001493152-23-022296","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315223022296/ownership.xml","form_type":"4"}}]}